The U.S. Food and Drug Administration (FDA) has given Entrada Therapeutics permission to launch a Phase 1b clinical…
Articles by Marisa Wexler, MS
Five people with oculopharyngeal muscular dystrophy (OPMD) — a type of muscular dystrophy marked by muscle weakness affecting…
A Phase 1 clinical trial testing SAT-3247, an oral treatment candidate for Duchenne muscular dystrophy (DMD), is now done…
A fundraiser through the online role-playing game World of Warcraft has raised more than $2 million to support CureDuchenne,…
Treatment with oral therapy ifetroban led to improvements in measures of heart function in people with Duchenne muscular dystrophy…
The Muscular Dystrophy Association (MDA) has announced its 2025 Legacy Awards, and will honor two individuals who have made…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to DYNE-101, a treatment candidate for myotonic…
Capricor Therapeutics has completed its submission of a biologics license application (BLA) seeking U.S. approval of deramiocel, the…
The Muscular Dystrophy Association (MDA) has awarded nearly two dozen new grants to fund research into various forms of…
The investigational oral therapy sevasemten significantly reduced markers of muscle damage in people with Becker muscular dystrophy (BMD)…